New study checks if etrasimod passes into breast milk

NCT ID NCT07153159

Recruiting now Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing how much of the drug etrasimod ends up in breast milk. Eight healthy breastfeeding women will take a 2 mg pill daily for a week while staying at a clinic. They will not breastfeed their babies during the study to keep them safe. Researchers will measure drug levels in blood and milk to understand how much passes through.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Etrasimod (oral tablet, 2 mg once daily for 7 days)
What this could lead to: If successful, this study will provide crucial data on how much etrasimod enters breast milk, helping doctors advise breastfeeding women about its safety.
What could go wrong: This is a very small, early-phase study in healthy women, not patients. It only measures drug levels, not health outcomes, so it cannot prove safety or effectiveness for any condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY PARTICIPANT

Contacts and locations

Locations

Pfizer Clinical Research Unit - Brussels
RECRUITING

Brussels, Bruxelles-capitale, Région de, B-1070, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.